All analyses
AI analysis

Asiri Surgical Hospital PLC: research report

Fairly valuedbullishNov 10, 2026

Evidence points to a stronger hospital at a modest valuation: September net profit rose 50.2% as margins reached a record. The catch is that the quarter supplied 33.6% of trailing earnings.

Reports without a focus are public, one per stock per day. Generation usually takes about 15 minutes, and we'll notify you when it's ready.

Why bullish

  • September-quarter net profit rose 50.2% year-on-year, with gross margin reaching 45.5%, the best September result in seven comparable periods.
  • The share trades at 8.7 times trailing profit, below the healthcare peer median of 13.9 times, while net debt fell to LKR 1.2 billion at the latest audited year-end.

Against this. The latest quarter generated 33.6% of trailing EPS, so the earnings supporting the current P/E rely heavily on one strong quarter.

Operating margin
18.1%
latest quarter
Net margin
15.4%sector 13.0%
from 12.1% a year earlier, revenue +17.6%
Return on equity
12.0%
twelve months to Sep 30, 2026, unaudited
P/E
7.0sector 11.8
earnings Rs 1.84 per share, year to Sep 2026
P/B
0.83sector 1.36
book Rs 15.34 per share
Dividend yield
0.00%sector 0.00%
trailing twelve months

Current figures, updated daily from filings to Sep 30, 2026. The report below was written on Nov 10, 2026. Sector figures are the median of 6 listed companies in the same sector.

Overview

Asiri Surgical Hospital operates a specialist private hospital serving surgical, diagnostic and post-operative care needs. The latest filed quarter showed a marked strengthening in profitability, led by higher revenue and record gross and net margins against its own comparable September history.

The market-wide valuation starting point is Fairly valued, scoring 55 out of 100 across book value, earnings and dividends. The evidence moves the assessment to bullish because operating performance and balance-sheet repair are stronger than that middle-of-market starting point suggests.

Price performance

At LKR 13.40 on 10 November 2026, AMSL was down 43.7% over six months, compared with a 6.7% fall in the ASPI. It has nevertheless risen 32.7% over one month against a 6.0% ASPI gain, showing that the recent rebound follows a much larger earlier retreat rather than a consistently stronger record.

The price sits 22.0% up its 52-week range from the low, leaving it near the lower end of that range. The three-year record contains four falls of 15% or more, with the deepest decline 64.1% and not yet recovered; these are records of past volatility, not price levels.

Median daily turnover was LKR 1.7 million over 60 sessions. A LKR 1 million order is about 59% of what trades on a typical day, a large part of a day's trading.

Valuation

At 8.7 times P/E, AMSL asks for LKR 8.70 for every LKR 1 of trailing profit, below the healthcare peer median of 13.9 times. Its P/B of 0.87 means the market value is 87 cents for each rupee of net assets, against a sector median of 2.01, while audited FY2026 return on equity was 10.7%; the lower P/B is therefore not simply explained by an unusually weak return on equity.

The company’s own P/E record says it is cheaper than 68% of days since February 2012. A buyer at the present multiple is relying on a September quarter that provided 33.6% of trailing EPS; if that quarter had earned its year-ago net margin, P/E would be 9.4 times instead.

There is no current dividend yield and no dividend is on record in the last two years. That removes income from the valuation case despite the share's lower earnings and book multiples.

News and sentiment

Direct coverage is thin: the 90-day news set contains three material articles, one positive and two negative. The most material item, reported on 17 August 2026, concerned Softlogic Holdings and noted that a tax dispute involving Asiri Surgical Hospital remains under appeal.

There are no confirmed or undated corporate actions in the supplied record, and no dividend is currently on record.

Financials

September-quarter revenue rose 17.6% year-on-year to LKR 2.3 billion, while net profit increased 50.2% to LKR 360 million. Gross margin improved from 43.8% to 45.5%, operating margin was 18.1% with no comparable prior-year operating margin available in the filed series, and net margin improved from 12.1% to 15.4%. Gross margin was the best of seven comparable September quarters and net margin among the best two of seven, so this was not merely a nominal revenue increase.

The LKR 64 million gap between operating and net profit shows finance costs, tax and other below-operating items still reduced earnings, but the latest quarter retained most of its operating profit. LKR 37 million of group profit belonged to minority shareholders, so group profit is not wholly attributable to the ordinary shares being valued.

At the latest audited year-end, revenue was LKR 7.7 billion and net profit LKR 940 million, up 151.6% year-on-year. Equity attributable to owners was LKR 7.6 billion, and the share count was unchanged at 528.5 million between the latest balance sheet and today, so the reported per-share figures are not being mechanically reshaped by a recent rights issue or subdivision.

Risks

The main financial risk is cash conversion. In FY2026, operating cash flow was only 0.33 times operating profit and free cash flow was negative LKR 95 million, meaning accounting profit did not largely arrive as cash after capital spending. For a hospital that invests in clinical facilities, that leaves future cash generation important even though reported earnings improved.

Debt is less burdensome than a year earlier: net debt was LKR 1.2 billion and gearing was 24.2% of owners' equity. Interest cover was 4.78 times, meaning operating profit covered the finance bill fewer than five times, while the 1.09 current ratio left only a modest excess of short-term assets over bills due within a year.

The wider market backdrop adds a cost risk. As at 10 November 2026, inflation was 8.3% after a 100 basis-point policy-rate increase; this is market context rather than company-specific news, but higher borrowing and operating costs would matter to a capital-intensive hospital.

Outlook

As at 10 November 2026, the next documented catalyst is the interim quarter ending 31 December 2026, expected to be filed between 3 and 14 February 2027. It will show whether the stronger September revenue and profitability were sustained and whether operating cash generation improved; the supplied data cannot establish either outcome in advance.

The unresolved tax dispute cited in the 17 August report remains a separate uncertainty because its potential financial terms are not supplied. Healthcare-sector news was otherwise quiet, providing no company-specific evidence on demand, pricing or expansion beyond the filed results.

About this report. Generated on Nov 10, 2026 from market data up to Nov 10, 2026, 3 material news articles over 90 days and financials to Sep 30, 2026, and scored 55 of 100 on value (fairly valued) when it was written. Every figure is drawn from EquityLK's own data on this company. AI research can contain errors, so treat it as a starting point, not investment advice.

Previous reports